This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Saw Palmetto
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Our depth — beyond the mirror
Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.
▸ Editor's verdict SKIP-FOR-NOW MEDIUM
"Genuine 5-alpha-reductase inhibition makes saw palmetto useful for androgenetic alopecia and BPH — but for a 20yo athlete with presumably normal androgen status, anti-androgenic supplementation has real downsides: potential mood/libido/recovery impacts, blunted training response. Cite-able evidence for hair-loss benefit is modest (smaller effect than finasteride). Only worth using if hair loss is already evident AND finasteride is rejected AND lab-monitored. Default: skip until specific indication arises."
▸ Decision matrix by user profile Per-archetype
| Archetype | Verdict | Rationale |
|---|---|---|
Dylan (20yo MMA athlete, no MPB onset, normal androgens presumed) | SKIP | No indication. Anti-androgenic load is the wrong directional pressure for a competitive athlete optimizing for drive, recovery, and training response. Even modest DHT reduction is unhelpful in this archetype. Revisit only if (a) MPB clearly emerges in mid-late 20s AND (b) finasteride is rejected for sexual-side-effect concerns AND (c) labs (T, fT, DHT, PSA baseline) document baseline before any trial. Default action: don't start. |
Athletic male 18-35, no specific indication | SKIP | Same logic as Dylan. Modest 5αR effect, weaker than finasteride, no documented benefit for performance/recovery, real anti-androgenic side-effect risk in the bottom 10-15% of users. No upside. |
Early-onset AGA, 20-30, finasteride rejected | POSSIBLE | Modest evidence base (Prager 2002, Evron 2020, Ablon 2023). Smaller effect than finasteride but real. Pair with topical minoxidil 5%. Lab baseline (T, fT, DHT, PSA) before starting; reassess at 16-24 weeks via trichoscopy/photography. |
Aging male 50+ with BPH symptoms (LUTS) | POSSIBLE | Permixon only. Vela-Navarrete 2018 meta-analysis supports Permixon comparable to tamsulosin with better sexual side-effect profile. Skip generic American product (CAMUS failed). Use 320 mg/day Permixon ≥12-24 weeks. |
Hormone-sensitive cancer history (prostate, breast, testicular) | CAUTION | / consult oncologist. Anti-androgenic activity is mechanistically relevant; no clinical signal one way or the other for risk modification. Coordinate with treating physician. |
Liver disease / elevated baseline LFTs | CAUTION | Hepatotoxicity rare but case reports exist. Avoid chronic use or monitor LFTs every 3 months. |
Pre-surgical (within 2 weeks) | HOLD | Antiplatelet activity; bleeding risk. |
Pregnancy / breastfeeding / partner-pregnancy-planning | HARD | BLOCK (theoretical). Anti-androgens are teratogenic for male fetuses (hypospadias risk). Even handling crushed tablets carries theoretical risk. Women avoid; partners of pregnant women: not a strict block but avoid out of conservatism. |
Concurrent finasteride / dutasteride use | REDUNDANT | Don't stack. If on finasteride and considering switching, taper finasteride out before starting saw palmetto. |
Athlete subject to in-competition WADA / USADA testing | CHECK STATUS | Saw palmetto is not on the WADA prohibited list; not a doping concern. Some endurance/strength claims for saw palmetto are unfounded — it's not ergogenic. |
- Dylan (20yo MMA athlete, no MPB onset, normal androgens presumed)SKIP
No indication. Anti-androgenic load is the wrong directional pressure for a competitive athlete optimizing for drive, recovery, and training response. Even modest DHT reduction is unhelpful in this archetype. Revisit only if (a) MPB clearly emerges in mid-late 20s AND (b) finasteride is rejected for sexual-side-effect concerns AND (c) labs (T, fT, DHT, PSA baseline) document baseline before any trial. Default action: don't start.
- Athletic male 18-35, no specific indicationSKIP
Same logic as Dylan. Modest 5αR effect, weaker than finasteride, no documented benefit for performance/recovery, real anti-androgenic side-effect risk in the bottom 10-15% of users. No upside.
- Early-onset AGA, 20-30, finasteride rejectedPOSSIBLE
Modest evidence base (Prager 2002, Evron 2020, Ablon 2023). Smaller effect than finasteride but real. Pair with topical minoxidil 5%. Lab baseline (T, fT, DHT, PSA) before starting; reassess at 16-24 weeks via trichoscopy/photography.
- Aging male 50+ with BPH symptoms (LUTS)POSSIBLE
Permixon only. Vela-Navarrete 2018 meta-analysis supports Permixon comparable to tamsulosin with better sexual side-effect profile. Skip generic American product (CAMUS failed). Use 320 mg/day Permixon ≥12-24 weeks.
- Hormone-sensitive cancer history (prostate, breast, testicular)CAUTION
/ consult oncologist. Anti-androgenic activity is mechanistically relevant; no clinical signal one way or the other for risk modification. Coordinate with treating physician.
- Liver disease / elevated baseline LFTsCAUTION
Hepatotoxicity rare but case reports exist. Avoid chronic use or monitor LFTs every 3 months.
- Pre-surgical (within 2 weeks)HOLD
Antiplatelet activity; bleeding risk.
- Pregnancy / breastfeeding / partner-pregnancy-planningHARD
BLOCK (theoretical). Anti-androgens are teratogenic for male fetuses (hypospadias risk). Even handling crushed tablets carries theoretical risk. Women avoid; partners of pregnant women: not a strict block but avoid out of conservatism.
- Concurrent finasteride / dutasteride useREDUNDANT
Don't stack. If on finasteride and considering switching, taper finasteride out before starting saw palmetto.
- Athlete subject to in-competition WADA / USADA testingCHECK STATUS
Saw palmetto is not on the WADA prohibited list; not a doping concern. Some endurance/strength claims for saw palmetto are unfounded — it's not ergogenic.
▸ Subjective experience (deep)
For a young athletic male with no indication, the most likely subjective experience is nothing. At 320 mg/day standardized extract, baseline-normal androgen physiology has minimal headroom for noticeable change in 8-12 weeks. Some users report:
- Mild reduction in libido / morning erections at 2-6 weeks (~10-15% of users at typical dose; more common at 600+ mg/day). Reversible on discontinuation.
- Subtle "softer" sense of drive/aggression — rarely reported in young athletes, more common in older men on higher doses. Likely AR-modulation effect rather than DHT reduction per se.
- Mild GI upset in first 1-2 weeks (~5-10%, especially on empty stomach).
- Headache rare, mild when present.
- In AGA users: subjectively reduced shedding usually emerges 8-16 weeks. Hair count changes need photographic comparison to detect reliably; users overestimate "feel" results.
- In BPH users (Permixon): reduced nocturia is the earliest noticeable benefit, 4-8 weeks. Urinary flow improvement is slower (12+ weeks).
No acute "feel" effect. Saw palmetto is not an acute-dosed compound. Onset of any noticeable change is 4-12+ weeks. This is one reason discontinuation is common in casual users — they expect a feel and don't get one.
▸ Tolerance + cycling deep dive
- No tolerance documented. 18-24 month trials show sustained effect (positive trials) or sustained null (CAMUS).
- No cycling needed. Continuous daily use is the studied protocol.
- No withdrawal on discontinuation. Effects reverse gradually if discontinued (3-12 months for AGA).
- No CNS receptor downregulation concern. Mechanism is peripheral hormonal/enzymatic, not central neurotransmitter.
▸ Stacking deep dive
Synergistic with
- Stinging nettle root (Urtica dioica) — combined formulas (Prostagutt-Forte, German Rx) show additive BPH benefit. Nettle root binds SHBG and may free up T while saw palmetto reduces DHT, theoretically balancing.
- β-sitosterol (standalone) — already a major component; supplementing additional β-sitosterol may amplify the 5αR-inhibitor signal modestly (Prager 2002 combo).
- Pumpkin seed oil / pumpkin seed extract — anecdotal AGA stack; weak evidence base, but synergistic on a phytosterol basis.
- Pygeum africanum (African plum bark) — common combo for BPH, weak but consistent evidence.
- Topical minoxidil 5% — different mechanism (peripheral vasodilator / hair-cycle modifier). Pairing saw palmetto + minoxidil is the standard "softer" AGA protocol when finasteride is rejected.
- Zinc 15-30 mg/day — anecdotal AGA stack; weak independent evidence; zinc is a mild 5αR inhibitor in vitro.
Avoid stacking with
- Finasteride / dutasteride — redundant mechanism; no additive benefit; adds sexual side-effect risk without comparable efficacy gain.
- Other strong anti-androgens (spironolactone, bicalutamide) — additive feminization risk; only under specific physician-directed protocols (PCOS, prostate cancer, gender-affirming care — outside the scope of this file).
- Anticoagulants / antiplatelets (warfarin, aspirin >100 mg, clopidogrel) — additive bleeding risk via 5-LOX inhibition. Coordinate with prescriber.
Neutral / safe co-administration
- All of Dylan's V4 stack (Mg, NAC, citicoline, PS, DHA, curcumin, rhodiola, theanine, glycine, D3/K2, beta-alanine, vitamin C) — no known interactions.
- Creatine — neutral.
- Standard testosterone-supporting supplements (zinc, magnesium, D3) — neutral; saw palmetto does not lower T (only DHT).
- SSRIs, SNRIs — no documented interaction.
- Modafinil — no documented interaction.
▸ Drug interactions deep dive
Saw palmetto's metabolic profile:
- Minimal CYP interaction — in vitro studies show weak CYP2D6, CYP3A4, and CYP2C9 inhibition at high concentrations; clinical relevance considered minimal at standard 320 mg dose.
- Mild antiplatelet effect — likely via 5-LOX inhibition and fatty-acid contribution to platelet membrane composition.
Clinically significant interactions:
1. Anticoagulants / antiplatelets — additive bleeding
- Case reports of intraoperative bleeding and prolonged bleeding times. Discontinue 2 weeks before any surgery. With warfarin/clopidogrel/aspirin >81 mg, additional INR/platelet monitoring is reasonable.
2. Hormonal contraceptives — possible reduced efficacy
- Theoretical based on weak CYP3A4 effect; no documented clinical reduction. Probably not clinically relevant at 320 mg.
3. Iron supplements — separate by 2 hours
- Tannins in some extracts may chelate iron. Minor concern, easy to avoid.
4. PSA testing — interference
- Saw palmetto does NOT lower PSA at clinical doses (CAMUS sub-analysis). Finasteride/dutasteride do (~50%). For a patient being screened, this is a feature not a bug — saw palmetto won't mask a rising PSA.
5. Alcohol — minimal direct interaction. Both are mildly hepatotoxic at extreme doses; chronic heavy alcohol use + chronic saw palmetto could theoretically compound LFT elevation. Not a concern for Dylan (zero alcohol baseline).
6. NSAIDs (chronic) — additive antiplatelet/GI risk. Mild concern.
▸ Pharmacogenomics
- CYP polymorphism: Minimal clinical relevance. Saw palmetto is not primarily CYP-metabolized.
- SRD5A1/SRD5A2 polymorphisms (5α-reductase genes): Polymorphisms (e.g., V89L in SRD5A2) modulate response to 5αR inhibitors. Subjects with low baseline 5αR-2 activity may have less to inhibit; theoretical differential response to saw palmetto. No clinical genotyping currently used in saw palmetto decisions.
- AR CAG repeat polymorphism: Shorter CAG repeats associate with higher AR sensitivity and may correlate with stronger AGA predisposition + stronger response to AR-modulating interventions. Speculative for saw palmetto.
- HLA / hypersensitivity alleles: Saw palmetto-associated severe cutaneous reactions are not characterized in HLA studies; case reports too sparse.
- For Dylan: 23andMe results (June 2026) won't drive saw palmetto decision directly. AR CAG repeat is inferable from raw data via Promethease for academic interest; not actionable.
▸ Sourcing deep dive
| Path | Vendor | Cost | Reliability | Notes |
|---|---|---|---|---|
| Permixon (gold standard) | Pierre Fabre, EU pharmacy / online EU pharmacy | ~$25-40/mo (320 mg/day) | High (Rx in some EU countries; OTC in others) | Hexanic supercritical CO2 extract; only Serenoa preparation with consistent positive RCT data. Not widely available in US — requires EU import or specialty pharmacy. |
| Prostagutt Forte / Prostagutt Uno | Schwabe (Germany) | ~$25-35/mo | High (German Rx-equivalent OTC) | Saw palmetto + nettle root combination; widely used in Germany; positive trial data. |
| Life Extension Saw Palmetto/Pygeum | Life Extension, iHerb | $15-20/mo | Medium-high | US supplement; specifies supercritical CO2 extraction; among the better US options. |
| NOW Foods Saw Palmetto Extract | NOW, Amazon/iHerb | $8-12/mo | Medium | Standardized to 85-95% fatty acids; broadly available; quality acceptable but extract solvent often unspecified. |
| Generic store-brand (CVS, Walgreens, GNC) | Various | $5-15/mo | Low-medium | Quality variable. Many failed in CAMUS-era ConsumerLab testing for fatty-acid content vs label claim. Avoid for any clinical purpose. |
| Bulk berries / dry powder | Herbal suppliers | <$10/mo | Very low | Negligible bioavailability of active fatty acids without lipid-extraction processing. Skip. |
For Dylan: Skip — no indication. If revisiting in future, Permixon-equivalent or Life Extension Supercritical-Extracted Saw Palmetto is the floor for any therapeutic trial. Generic American product is what failed CAMUS.
Cost ceiling: Even gold-standard Permixon is $25-40/month. Not a cost-driven decision.
▸ Biomarkers to track (deep)
Baseline (before any therapeutic trial)
- Total testosterone, free testosterone — baseline reference; saw palmetto should not lower T (only DHT).
- DHT — primary mechanistic marker. Expect 10-30% reduction at therapeutic dose (much less than finasteride).
- PSA — baseline reference; saw palmetto does not suppress PSA (unlike finasteride, which suppresses ~50%).
- SHBG — baseline reference if nettle root co-administered (nettle root binds SHBG).
- LFTs (ALT, AST, GGT, bilirubin) — hepatic baseline.
- CBC + platelet count — pre-antiplatelet baseline.
- Trichoscopy / standardized photography (if AGA indication) — Norwood-Hamilton stage, hair count in target zones, miniaturization ratio. Required for any honest AGA efficacy assessment.
- IPSS (International Prostate Symptom Score) if BPH indication.
During use
- Subjective libido, morning erections, ejaculate volume — weekly VAS or simple journal for first 12 weeks.
- Subjective mood, drive, training motivation — daily VAS 1-10.
- Hair shedding count (AGA) — weekly hair-pull test or pillow/shower count.
- Urinary symptoms (BPH) — IPSS every 4-6 weeks.
Periodic
- 3-6 months: Repeat T, fT, DHT, PSA, LFTs. Verify DHT reduction; confirm T preserved; confirm LFTs stable.
- 12 weeks (AGA): Repeat trichoscopy/photography for objective efficacy.
- Annual: Full panel if chronic use.
Post-discontinuation
- 3 months off: DHT should normalize; subjective sexual function should return to baseline if any reduction occurred. Hair benefit (if any) will gradually reverse over 6-12 months.
▸ Controversies / open debates Live debate
1. Permixon vs generic — equivalent or not?
- Pro-equivalence: Some industry-funded reviews suggest fatty-acid content is the dominant determinant; brand differences overstated.
- Anti-equivalence: The CAMUS (generic ethanolic) null vs Vela-Navarrete (Permixon hexanic) positive is the cleanest natural experiment we have. AdisInsight 2022 review explicitly concludes Permixon is not equivalent to generic preparations.
- Probable answer: Extraction solvent and processing matter substantially. Hexanic supercritical CO2 (Permixon) preserves a fatty-acid profile that ethanolic extraction does not fully replicate. Generic American products often have lower or inconsistent active content per label claim. For any therapeutic intent, Permixon-equivalent supercritical CO2 product is the minimum acceptable.
2. AGA effect size vs finasteride
- Pro-saw palmetto: Sexual side effects much milder; long-term safety favorable; no PSA masking; can be discontinued without rebound; cheaper.
- Anti-saw palmetto: Effect ~40-60% of finasteride magnitude; no large head-to-head RCT; supplement-grade variability.
- Probable answer: Both real. Saw palmetto is a legitimate option for users who specifically reject finasteride's sexual side-effect risk, accepting smaller magnitude of effect. Not a substitute for finasteride in cases where maximum AGA suppression is the goal.
3. Female AGA / PCOS
- Limited but suggestive small-trial data. Spironolactone remains better-evidenced for female pattern hair loss and hyperandrogenism.
4. PSA effect / prostate cancer detection
- Saw palmetto does NOT suppress PSA at clinical doses (CAMUS sub-analysis). This is a feature — finasteride/dutasteride suppress PSA ~50%, which complicates prostate cancer screening. Saw palmetto users can be screened normally.
5. "Smaller doses, longer cycles" claims
- Some marketing pushes 50-100 mg dose protocols. No trial evidence below 320 mg/day. Sub-therapeutic.
6. Combination products (saw palmetto + pygeum + nettle + beta-sitosterol + pumpkin seed)
- Common in commercial blends. Marginal added evidence for the additions individually. Prostagutt-Forte (saw palmetto + nettle root) has the strongest RCT evidence of the combinations.
▸ Verdict change log
- 2026-05-13 — Initial verdict: SKIP-FOR-NOW / MEDIUM CONFIDENCE (auto-stub, dopamine.club seed). Anti-androgenic mechanism inappropriate for 20yo athlete without specific indication.
- 2026-05-14 — Confirmed verdict: SKIP-FOR-NOW / MEDIUM CONFIDENCE (thorough pass). Evidence review confirms: brand-dependent efficacy (Permixon yes, generic no), modest AGA effect smaller than finasteride, no documented benefit in healthy young athletic males, real but modest anti-androgenic side-effect risk. No reason to update verdict. Revisit trigger: documented MPB onset + lab baseline + decision to reject finasteride.
▸ Open questions / gaps Open
- Long-term (5-10+ year) outcomes in younger AGA users on saw palmetto monotherapy — no data exists.
- Head-to-head finasteride vs saw palmetto RCT with standardized hair-count outcomes — not adequately powered in existing literature.
- Brand-quality standardization — should the FDA mandate supercritical CO2 standard? No regulatory movement to date.
- Genetic predictors of response (SRD5A1/2, AR CAG) — no clinical genotyping algorithm yet.
- Topical-only protocols — emerging, but optimal vehicle, concentration, and frequency unsettled.
- Saw palmetto in tested athletes — confirmed not WADA-banned, but no studies examining whether modest DHT reduction impairs strength/power development in young men. Likely small effect, but unstudied.
- Mechanism of rare hepatotoxicity — case reports too sparse for causal model.
- For Dylan specifically: Would early-20s saw palmetto use accelerate or delay any latent MPB onset? No prospective data. The conservative default (skip until indication emerges) avoids this uncertainty entirely.
References
Bent et al. 2006 — STEP trial: saw palmetto for BPH (NEJM)
definitive negative for generic extract at standard dose.
View StudyBarry et al. 2011 — CAMUS trial: escalating-dose saw palmetto for BPH (JAMA)
definitive negative for ethanolic American extract at 3× dose, 18 months.
View StudyVela-Navarrete et al. 2018 — Permixon hexanic extract meta-analysis (BJU Int)
positive evidence base for Permixon brand specifically.
View StudyNovara et al. 2016 — Permixon meta-analysis
earlier Permixon-only meta confirming hexanic-extract benefit.
View StudyAdisInsight 2022 — Permixon hexanic extract review
extraction methodology dominates extract activity; brands not interchangeable.
View StudyPrager et al. 2002 — saw palmetto + β-sitosterol vs placebo in AGA (J Altern Complement Med)
first formal botanical-5αR-inhibitor AGA evidence.
View StudyEvron et al. 2020 — Saw palmetto in alopecia systematic review (Skin Appendage Disord)
pooled evidence, effect smaller than finasteride.
View StudyAblon et al. 2023 — 16-week RCT oral + topical saw palmetto for AGA (Clin Cosmet Investig Dermatol)
recent positive RCT with combined protocol.
View StudyLatest research
- rctOral and topical standardized saw palmetto oil for androgenetic alopecia — 16-week RCT80 subjects, 400 mg oral + 2-3% β-sitosterol topical for 16 weeks reduced hair fall and improved density vs placebo; effect modest, well-tolerated.
- reviewHexanic extract of Serenoa repens (Permixon) — review in symptomatic BPHConfirms Permixon (hexanic, supercritical CO2) is the only Serenoa preparation with consistent RCT evidence for LUTS/BPH; ethanolic and dry-powder American generics are not equivalent.
- reviewSaw palmetto in alopecia — systematic reviewPooled 5 RCTs + 2 cohorts (n=535). 60% subjective improvement, 27% increase in hair count, modest vs finasteride. Authors note effect size smaller than finasteride; no head-to-head dosing.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.